BioCentury
ARTICLE | Company News

Alnylam provides pipeline update

January 11, 2014 2:37 AM UTC

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) provided a pipeline update and said it expects to have six to seven programs in clinical development by YE15, exceeding the goals set in the company's original "Alnylam 5x15" plan. The company said it expects at least two programs in Phase III and five to six with human proof of concept (POC) data by that time. Alnylam's ALN-TTR02 is in the Phase III APOLLO trial to treat familial amyloidosis polyneuropathy (FAP), a predominant clinical manifestation of transthyretin (TTR)-mediated amyloidosis. Its ALN-TTRsc is in Phase II testing for TTR-mediated amyloidosis, with Phase III slated to start by year end. Early this year, the company will begin Phase I testing of ALN-AT3 to treat hemophilia and rare bleeding disorders, with initial data slated for late 2014.

The company said it expects to file INDs late this year or early next year for complement-mediated diseases product ALN-CC5, hepatic prophyrias product ALN-AS1 and hypercholesterolemia product ALN-PCSsc. The company also raised its YE13 cash guidance to about $350 million, from more than $320 million. ...